✦ LIBER ✦

Development of a Prostaglandin D2 Receptor Antagonist: Discovery of a New Chemical Lead.

✍ Scribed by Kazuhiko Torisu; Kaoru Kobayashi; Maki Iwahashi; Hiromu Egashira; Yoshihiko Nakai; Yutaka Okada; Fumio Nanbu; Shuichi Ohuchida; Hisao Nakai; Masaaki Toda

Publisher: John Wiley and Sons
Year: 2005
Weight: 22 KB
Volume: 36
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200546107

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Discovery of New Chemical Leads for Pros

Discovery of New Chemical Leads for Prostaglandin D2 Receptor Antagonists.

✍ Kazuhiko Torisu; Kaoru Kobayashi; Maki Iwahashi; Hiromu Egashira; Yoshihiko Naka 📂 Article 📅 2004 🏛 John Wiley and Sons ⚖ 9 KB 👁 1 views

Discovery of Orally Active Prostaglandin

Discovery of Orally Active Prostaglandin D2 Receptor Antagonists.

✍ Kazuhiko Torisu; et al. et al. 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 192 KB 👁 1 views

The Discovery and Synthesis of Novel Ade

The Discovery and Synthesis of Novel Adenosine Receptor (A2A) Antagonists.

✍ Julius J. Matasi; John P. Caldwell; Jinsong Hao; Bernard Neustadt; Leyla Arik; C 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 21 KB 👁 2 views

Discovery of a Potent, Non-Peptide Brady

Discovery of a Potent, Non-Peptide Bradykinin B1 Receptor Antagonist.

✍ Dai-Shi Su; et al. et al. 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 60 KB 👁 1 views

Discovery of a Potent and Selective Agon

Discovery of a Potent and Selective Agonist of the Prostaglandin EP4 Receptor.

✍ Xavier Billot; Anne Chateauneuf; Nathalie Chauret; Danielle Denis; Gillian Greig 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 70 KB 👁 2 views

A2A-selective adenosine receptor antagon

A2A-selective adenosine receptor antagonists: Development of water-soluble prodrugs and a new tritiated radioligand

✍ Christa E. Müller; Roland Sauer; Yuris Maurinsh; Rosa Huertas; Friederike Fülle; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 2 views

A 2A adenosine receptor (AR) antagonists are promising new drugs for the treatment of Parkinson's disease. Further potential therapeutic indications for A 2A AR antagonists include dementias, ischemias, and pain. Potent, selective A 2A AR antagonists have been developed, but their generally low wate